Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy

DOI XML XML 被引用文献4件

抄録

<jats:title>Abstract</jats:title><jats:p><jats:bold>Objective</jats:bold>—To determine the effect of the 5α-reductase inhibitor finasteride on prostatic diameter and volume, semen quality, and serum dihydrotestosterone (DHT) and testosterone concentrations in dogs with spontaneous benign prostatic hypertrophy (BPH).</jats:p><jats:p><jats:bold>Design</jats:bold>—Double-blind placebo-controlled trial.</jats:p><jats:p><jats:bold>Animals</jats:bold>—9 dogs with BPH.</jats:p><jats:p><jats:bold>Procedure</jats:bold>—Five dogs were treated with finasteride for 16 weeks (0.1 to 0.5 mg/kg [0.05 to 0.23 mg/lb] of body weight, PO, q 24 h); the other 4 received a placebo. Prostatic diameter, measured radiographically, prostatic volume, measured ultrasonographically, semen quality, and serum DHT and testosterone concentrations were evaluated before and during treatment. After receiving the placebo for 16 weeks, the 4 control dogs were treated with finasteride for 16 weeks, and evaluations were repeated.</jats:p><jats:p><jats:bold>Results</jats:bold>—Finasteride significantly decreased prostatic diameter (mean percentage decrease, 20%), prostatic volume (mean percentage decrease, 43%), and serum DHT concentration (mean percentage decrease, 58%). Finasteride decreased semen volume but did not adversely effect semen quality or serum testosterone concentration. No adverse effects were reported by owners of dogs in the study.</jats:p><jats:p><jats:bold>Conclusions and Clinical Relevance</jats:bold>—Results suggest that finasteride can be used to reduce prostatic size in dogs with BPH without adversely affecting semen quality or serum testosterone concentration. (<jats:italic>J Am Vet Med Assoc</jats:italic>2001;218:1275–1280)</jats:p>

収録刊行物

被引用文献 (4)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ